Investment co-led by Jonathan Milner and Cambridge Enterprise US-based R42 Group, ACF Investors, o2h Ventures, Syndicate Room and the Cambridge Angels investing Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours CAMBRIDGE, England–(BUSINESS WIRE)–Spirea Limited, a Cambridge company created to advance a new generation of … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Voice of the Industry: Consumer Health” report has been added to ResearchAndMarkets.com’s offering. In the Voice of the Industry Survey series, the analyst connects with industry professionals to explore trends and innovations. This report focuses on the consumer health industry, drawing on the Voice of the Industry: Consumer Health Survey. The global briefing … [Read more…]
LONDON–(BUSINESS WIRE)–AIBODY, the world’s first Physiology-as-a-Service platform, announced today that it will partner with Relias, the United States-based healthcare education and workforce development leader, to develop an innovative range of digital study materials for professional medical training. Specializing in healthcare education solutions, Relias helps more than 11,000 organizations and 4.5 million caregivers elevate care to … [Read more…]
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–$RDY #BayerHealthCare–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Dr. Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic equivalent of Nexavar® (sorafenib) Tablets in the U.S. market following the approval … [Read more…]
LYT-300 achieved systemic blood levels approximately nine-fold greater compared to previous reports with oral allopregnanolone.1 Allopregnanolone is a neurosteroid with proven efficacy that is currently only approved as a 60-hour intravenous infusion. LYT-300, an orally administered prodrug of allopregnanolone, is designed to be differentiated from synthetic analogs, which may not replicate the full target engagement … [Read more…]
Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model OXFORD, England–(BUSINESS WIRE)–Beckley Psytech Limited, a private company dedicated to addressing neurological and psychiatric disorders through … [Read more…]
No treatment effect observed in this patient population; substantial improvement in 6-minute walk test seen in both placebo and active groups Study adds to growing body of data supporting strong safety and tolerability profile of LYT-100 (deupirfenidone) Company will drive LYT-100 forward in other indications, with a focus on IPF where human clinical efficacy has … [Read more…]
U.S. News & World Report’s annual hospital survey again ranks Children’s Hospital Los Angeles among the top 10 pediatric hospitals in the nation LOS ANGELES–(BUSINESS WIRE)–#childrenshealth–Children’s Hospital Los Angeles (CHLA) continues its streak of being California’s top hospital for pediatric care and specialty services, according to U.S. News & World Report’s 2022-23 Best Children’s Hospitals … [Read more…]
– First and Only FDA-approved Treatment Demonstrating Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – AMVUTTRA Met Primary and All Secondary Endpoints, with Significant Improvement in Polyneuropathy, Quality of Life and Gait Speed Relative to External Placebo – – Company Expects to Launch in Early July, with Value-Based Agreements to … [Read more…]
OXFORD, England & PASADENA, Calif.–(BUSINESS WIRE)–$RKLY #RKLY–Rockley Photonics Holdings Limited (NYSE: RKLY), a global leader in photonics-based health monitoring and communications solutions, announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022, according … [Read more…]
